Hydrocephalus

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
Weakness, GBM, Patient, Progression-free survival, Headache, Drug, Urinary tract infection, Thrombosis, NK, PFS, EDT, TMZ, DRI, Balance disorder, Platelet, Cytokine release syndrome, KPS, Glioblastoma, NKG2D, Appetite, Neurotoxicity, Hydrocephalus, ASCO, Performance status, Fatigue, OS, Society, Annual general meeting, Medical imaging

INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).

Key Points: 
  • INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).
  • “The current standard-of-care for newly diagnosed GBM has not advanced progression-free survival (PFS) beyond 4-7 months or overall survival beyond 14-16 months for over two decades,” said William Ho, CEO and co-founder, IN8bio.
  • “We’re excited to update the status of patients who received INB-200 for front-line GBM in addition to standard-of-care at the upcoming ASCO Annual Meeting.
  • Autologous DeltEx DRI is a gene-modified autologous gamma-delta T cell therapy designed for the treatment of newly diagnosed GBM patients receiving maintenance TMZ therapy.

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期四, 三月 21, 2024
Research, SAFE, Growth, HOPE, CE, Patient, PMR, ACTION, UKCA, Hydrocephalus, ECMO, News, MDR, Pediatrics, Malnutrition, Nursing care plan, Marketing, FDA, Video game

Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.

Key Points: 
  • Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.
  • Gross margin for the fourth quarter of 2023 was $1.03 million, compared to $0.30 million in the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $5.96 million, compared to $5.22 million in the fourth quarter of 2022.
  • Sales, marketing, general, and administrative expenses for the fourth quarter of 2023 were $6.70 million, compared to $8.71 million in the fourth quarter of 2022.

CereVasc's eShunt® System Study Data Presented at the ABC WIN Seminar

Retrieved on: 
星期二, 一月 23, 2024
Hydrocephalus, Patient, Subarachnoid hemorrhage, ABC, DSM-IV codes, FDA, NPH, Treatment

BOSTON, Jan. 23, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d'Isere.

Key Points: 
  • BOSTON, Jan. 23, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d'Isere.
  • "We are pleased for our team to share the initial results of these thirty-one patients who have been treated with the eShunt System across multiple hydrocephalus etiologies and warrants the study of the device in a pivotal trial setting," said Dr. Pedro Lylyk, Director General of ENERI.
  • Dan Levangie, CereVasc President & CEO stated, "We are grateful to ABC WIN for the opportunity to have Dr. Lylyk present the encouraging data from our investigators in the trials of the eShunt System.
  • We are looking forward to leveraging the experience gained in these studies to support our pivotal study this year."

Dr. Ghassan Kassab Joins Anuncia Medical's Board, Elevating Future Product Innovation

Retrieved on: 
星期二, 一月 16, 2024
Entrepreneurship, Senior, Therapy, Biological engineering, CSF, Engineering, University, Hydrocephalus, Chemical substance, NIH, Purdue University, FDA, Medtronic, Cerebrospinal fluid, General partnership, Chemical engineering

In this role, Dr. Ghassan will provide guidance and support for the continued commercialization of the ReFlow™ Mini Flusher Device and future innovation to significantly improve patient access and care.

Key Points: 
  • In this role, Dr. Ghassan will provide guidance and support for the continued commercialization of the ReFlow™ Mini Flusher Device and future innovation to significantly improve patient access and care.
  • Dr. Ghassan joins an active, expert group of industry leaders committed to helping Anuncia redefine clinical approaches to cerebrospinal fluid dysfunctions, including hydrocephalus.
  • Dr. Kassab is a successful serial entrepreneur who brings decades of academic and industry experience to Anuncia.
  • We are thrilled that Dr. Kassab has joined our Board to help drive these future innovations," stated Elsa Chi Abruzzo, CEO of Anuncia.

Rhaeos, Inc. Strengthens Leadership Team with Appointment of Dr. David Limbrick as Chief Medical Officer

Retrieved on: 
星期二, 十一月 28, 2023
CNS, Principal, Research, Chicago Innovation Awards, Neuroimaging, Northwestern University, Neurosurgical anesthesia, Public service, Accreditation, Chiari malformation, Humanism, Patient, Accreditation Council, Virginia Commonwealth University, Congress of Neurological Surgeons, FDA, Neuro, Hydrocephalus, CMO, Doctor of Philosophy, Congress, Skin, Quality of life, Pediatric neurosurgery, Veterinary medicine, Medical device, Medicine, MD, Chiari, Neurosurgery

EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).

Key Points: 
  • EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).
  • Dr. Limbrick is currently a Professor at Virginia Commonwealth University, where he joined as the Chair of the Department of Neurosurgery in 2023.
  • "I am very excited to join the Rhaeos team after collaborating closely with them for the past two years," stated Dr. Limbrick.
  • The company looks forward to the continued advancement of their mission to have a global impact on neurosurgery and hydrocephalus management.

Myrtelle Announces Presentation at Hydrocephalus Association & Rudi Schulte Research Workshop on Developing Non-Invasive Hydrocephalus Therapies: Molecular and Cellular Targets

Retrieved on: 
星期四, 九月 28, 2023
Health, Neurology, Genetics, Clinical Trials, Research, Science, Biotechnology, CD, Canavan disease, Inc., Natural history, Gene, Clinical trial, Mutation, ASPA, Associate, Chromosome 11, MRI, Magnetic resonance imaging, Patient, Preyasi Raave, White matter, Hydrocephalus, FIH, Medical imaging

These improvements in treated patients contrast the deterioration in untreated age-matched CD patients based on natural history.

Key Points: 
  • These improvements in treated patients contrast the deterioration in untreated age-matched CD patients based on natural history.
  • MRI-based improvements are correlated with improvements in motor and cognitive function in treated patients, which will be presented at upcoming conferences.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme aspartoacylase.
  • The oligodendrocyte-targeting rAAV vector-based gene therapy is intended to restore ASPA function and brain development in patients with CD.

Inaugural World Hydrocephalus Day

Retrieved on: 
星期四, 九月 7, 2023
Headache, Brain, Research, Cerebrospinal fluid, Organization, School, Hydrocephalus, Patient, Water, Deficit spending, Social, Nausea, Diagnosis, Horror Wears Blue, NPH, Caregiver, Nursing, MD

Bethesda, MD, Sept. 07, 2023 (GLOBE NEWSWIRE) -- On September 20, 2023, the world will come together to observe the inaugural World Hydrocephalus Day, a day dedicated to raising awareness about hydrocephalus and showing support for individuals living with this complex neurological condition.

Key Points: 
  • Bethesda, MD, Sept. 07, 2023 (GLOBE NEWSWIRE) -- On September 20, 2023, the world will come together to observe the inaugural World Hydrocephalus Day, a day dedicated to raising awareness about hydrocephalus and showing support for individuals living with this complex neurological condition.
  • World Hydrocephalus Day aims to shed light on this often misunderstood condition and promote worldwide unity among patients, caregivers, healthcare professionals, and advocacy organizations.
  • World Hydrocephalus Day welcomes all to unite in shaping a brighter future for those with hydrocephalus.
  • For more information about World Hydrocephalus Day and how to get involved, please visit https://www.hydroassoc.org/whd

CereVasc eShunt® System Study Data Presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Marseille

Retrieved on: 
星期三, 九月 13, 2023
Hydrocephalus, Sagrada Família, DSM-IV codes, Trial of the century, Congress, Subarachnoid hemorrhage, CH, Patient, Intracranial pressure, Pharmaceutical industry, Medical device

Trial data reporting the investigational use of the eShunt System in patients with hydrocephalus secondary to subarachnoid hemorrhage was presented by Ivan Lylyk, M.D., one of the lead investigators based at Clínica La Sagrada Familia in Buenos Aires, Argentina.

Key Points: 
  • Trial data reporting the investigational use of the eShunt System in patients with hydrocephalus secondary to subarachnoid hemorrhage was presented by Ivan Lylyk, M.D., one of the lead investigators based at Clínica La Sagrada Familia in Buenos Aires, Argentina.
  • The study, conducted under the leadership of Pedro Lylyk, M.D., represents the first-ever treatment with the eShunt System and the world's first endovascular treatment of CH.
  • "We are excited by the initial data demonstrating the potential to provide patients a minimally invasive treatment for communicating hydrocephalus.
  • The data presented at ESMINT bolster our confidence in the potential of the Company's minimally invasive treatment of hydrocephalus as we transition to the pivotal clinical trial in early 2024."

Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System

Retrieved on: 
星期三, 八月 9, 2023
Medical Devices, Health, Neurology, Health Technology, Research, Science, Radiation, PMR, HOPE, Portable, Multimedia, Index, MRI, Hydrocephalus, Data analysis, Patient, Neurosurgery, Hospital, Pediatric neurosurgery, FDA, Nationwide, Medical imaging, Nursing, Hyperfine structure

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition).
  • The study used pediatric hydrocephalus as an index condition to assess if Swoop® system images can be used to accurately detect shunt malfunctions and assess ventricular size.
  • "The Swoop® system represents a promising shift in brain imaging.
  • Our collaboration with Hyperfine, Inc. paves the way for improvements in brain imaging, benefiting this vulnerable patient population."

2022 Gerson L'Chaim Prize Brings Hope, Healing to Children with Spinal Deformities in Ethiopia

Retrieved on: 
星期一, 八月 7, 2023
Certified Registered Nurse Anesthetist, Brain, AMH, Surgeon, Education, HIV, Cleft lip and cleft palate, American Jewish Joint Distribution Committee, CURE, Disability, Spina bifida, To Life, Hope, Social stigma, Movement, Organization, Hydrocephalus, Hospital, Patient, Nursing, Clubfoot, Haggadah, CURE International, Tim Tebow, Health, Elective surgery, Dentistry, Prize, Life

Dr. Nunn serves as medical director and orthopedic surgeon at CURE Ethiopia , a charitable pediatric hospital in Addis Ababa, Ethiopia.

Key Points: 
  • Dr. Nunn serves as medical director and orthopedic surgeon at CURE Ethiopia , a charitable pediatric hospital in Addis Ababa, Ethiopia.
  • The L'Chaim ('To Life' in Hebrew) Prize was launched in 2016 through the generosity of AMH Co-Founders Rabbi Erica and Mark Gerson.
  • An estimated 50,000 children in Ethiopia urgently need interventions for spinal deformities.
  • AMH Co-Founder and Prize sponsor Mark Gerson observed, "Dr. Nunn is an excellent choice for this year's L'Chaim Prize Laureate.